Panel 7: Perspectives on PrEP Implementation

Public Sector Payor Perspective

Claire Foreman, London Specialised Commissioning Group

Tuesday 12 June 2012
Public Payor Perspective

PrEP in context of

• NHS free at point of use
• Promoting public health and equity AND meeting local needs
• Services commissioned on basis of evidence and NICE approval for access to drugs
• Acting as the agents of patients AND the tax payer
• ‘Nicholson Challenge’ of £20 billion savings by 2015
As the agent of patients…

• Does it work? Will it improve outcomes for individuals?
• Do the benefits outweigh the risk of harm?
• Does it add value to patient choice and experience?
• Is it a realistic choice for patients? What are the responsibilities of patients?
• How will we define entitlement?
• Where will it be available?
• How will we monitor implementation?
As the agent of the taxpayer…

• Is it a priority? Does it fit with health policy?
• Does it add value to individual and public health?
• Is it a realistic option? How does it compare to the options we already have?
• What are the cost implications now and for the future?
• What might be the unintended consequences?
• Who will pay and how?
• Does it meet the QIPP (Quality Innovation Productivity and Prevention) agenda?
PrEP - other thoughts and questions …

- Are we in the lab or the consulting room?
- Will this expand or constrain HIV prevention efforts?
- Is this the right priority?
- If it does add value, when will we know?
- To what extent should the cost of drugs reflect their use?